Top Court in India Rejects Novartis Drug Patent – ‘Evergreening’ Ban to Cut into Big Pharma’s Mega Profits

India’s top court has put a stop to drug companies’ stranglehold on drugs. When a new drug’s patent expires, pharmaceutical companies simply change the chemical composition a bit and request a new patent for essentially the same drug. The process, called “evergreening” will no longer be recognized in India as producing a new, patentable drug – opening the doors to more affordable medicine.

Leave a Reply